AKTX — Akari Therapeutics Share News
0.000.00%
Last trade - 00:00NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:42 PM
Brief: Akari Therapeutics Announces $5.5 Million Private Placement Offering
NASDAQ RESUMED AT 10:27 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:22 AM
Granted Major European Patent For Ph1 Adc Payload Platform
Brief: Akari Therapeutics Secures Australian Patent Approval
NASDAQ RESUMED AT 10:09 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:59 AM
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Akari Therapeutics To Change ADS Ratio To 1 ADS Per 80,000 Ordinary Shares
Brief: Akari Therapeutics Releases CEO Corner Segment With CEO Abizer Gaslightwala
Brief: Akari Therapeutics Announces $5 Million Financing
Brief: Akari Therapeutics Announces Preclinical Data On AKTX-101 For Pancreatic Cancer
Brief: Akari Therapeutics Provides Corporate Update
Brief: Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag As Interim Chief Financial Officer
On October 22 Appointed Kameel Farag As Interim CFO - SEC Filing
Brief: Akari Therapeutics Announces Launch of CEO Corner Platform